Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure

Απλή σελίδα τεκμηρίου
dc.contributor.authorMilionis, H. J.en
dc.contributor.authorElisaf, M. S.en
dc.contributor.authorTselepis, A.en
dc.contributor.authorBairaktari, E.en
dc.contributor.authorKarabina, S. A.en
dc.contributor.authorSiamopoulos, K. C.en
dc.date.accessioned2015-11-24T16:52:28Z
dc.date.available2015-11-24T16:52:28Z
dc.identifier.issn0272-6386-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/9889
dc.rightsDefault Licence-
dc.subjectapolipoprotein(a)en
dc.subjectlipoprotein(a)en
dc.subjectchronic renal failureen
dc.subjectcontinuous ambulatory peritoneal dialysisen
dc.subjecthemodialysisen
dc.subjectcoronary-artery diseaseen
dc.subjectambulatory peritoneal-dialysisen
dc.subjectlp(a) glycoprotein phenotypesen
dc.subjecthemodialysis-patientsen
dc.subjectserum lipoprotein(a)en
dc.subjectplasma-concentrationsen
dc.subjectgenetic-polymorphismen
dc.subjectalbuminen
dc.subjectparametersen
dc.subjectcapden
dc.titleApolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failureen
heal.abstractPatients with renal failure have an increased incidence of atherosclerotic disease. Numerous studies have shown that these patients show increased serum lipoprotein(a) [Lp(a)] concentrations compared with the control population. However, variable alleles at the apolipoprotein(a) [apo(a)] gene locus determine to a large extent the Lp(a) concentration in the general population. We therefore undertook the present study to evaluate apo(a) phenotypes and Lp(a) serum concentrations in a large number of patients with renal disease. Seventy-nine patients treated by hemodialysis (HD), 47 patients treated by continuous ambulatory peritoneal dialysis (CAPD), 68 patients with mild/moderate chronic renal failure (CRF) and serum creatinine levels of 1.8 to 8 mg/dL, and 73 healthy controls were studied. All patients showed significantly elevated median serum Lp(a) concentrations in comparison with controls: HD patients, 15.7 mg/dL (P < 0.01); CAPD patients, 20 mg/dL (P < 0.005); CRF patients, 15.1 mg/dL (P < 0.01) versus controls, 7 mg/dL. The greater Lp(a) values in all groups were not explained by differences in isoform frequencies, whereas their increase was apo(a)-type specific. Thus, patients in all groups with high-molecular weight (HMW) apo(a) isoforms showed a significant elevation of Lp(a) levels, whereas serum Lp(a) concentrations in patients with low-molecular-weight (LMW) isoforms were not significantly different from controls, except for CAPD patients, who presented increased serum Lp(a) concentrations. We conclude that in patients with renal failure, even of mild/moderate degree, as well as in patients with end-stage renal disease undergoing HD or CAPD, elevated Lp(a) concentrations are mainly observed in those with HMW apo(a) phenotypes. (C) 1999 by the National Kidney Foundation, Inc.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondary<Go to ISI>://000081266500013-
heal.journalNameAmerican Journal of Kidney Diseasesen
heal.journalTypepeer reviewed-
heal.languageen-
heal.publicationDate1999-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ